Articles dans des revues avec comité de lecture (396)
  1. 193. Awada, A., Gil, T., Whenham, N., Van Hamme, J., Besse-Hammer, T., Brendel, E., Delesen, H., Joosten, M. C., Lathia, C., Loembé, B. A., Piccart-Gebhart, M., & Hendlisz, A. (2011). Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. Journal of clinical pharmacology, 51(12), 1674-1684. doi:10.1177/0091270010386226
  2. 194. Heath, E. I., Lorusso, P., Ramalingam, S. S., Awada, A., Egorin, M. J., Besse-Hammer, T., Cardoso, F., Valdivieso, M., Has, T., Alland, L., Zhou, X., & Belani, C. P. (2011). A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational new drugs, 29(6), 1426-1431. doi:10.1007/s10637-010-9498-z
  3. 195. El Saghir, N. S., Tfayli, A., Hatoum, H. A., Nachef, Z., Dinh, P., & Awada, A. (2011). Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Critical reviews in oncology/hematology, 80(3), 433-449. doi:10.1016/j.critrevonc.2011.01.010
  4. 196. Klastersky, J., Gombos, A., Georgala, A., & Awada, A. (2011). Prevention of neutropenia-related events in elderly patients with hematological cancer. Aging health, 7(6), 829-842. doi:10.2217/ahe.11.69
  5. 197. Aftimos, P., & Awada, A. (2011). Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? Advances in therapy, 28(11), 973-985. doi:10.1007/s12325-011-0070-9
  6. 198. Mayer, E. L., Baurain, J.-F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Awada, A., Sy, O., & Llombart-Cussac, A. (2011). A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clinical cancer research, 17(21), 6897-6904. doi:10.1158/1078-0432.CCR-11-0070
  7. 199. Journé, F., Id Boufker, H., van Kempen, L., Galibert, M.-D., Wiedig, M., Sales, F., Theunis, A., Nonclercq, D., Frau, A., Laurent, G., Awada, A., & Ghanem, G. E. (2011). TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. British Journal of Cancer, 105(11), 1726-1732. doi:10.1038/bjc.2011.451
  8. 200. Otrock, Z. Z., Hatoum, H. H., Musallam, K. K., Awada, A., & Shamseddine, A. (2011). Is VEGF a predictive biomarker to anti-angiogenic therapy? Critical reviews in oncology/hematology, 79(2), 103-111. doi:10.1016/j.critrevonc.2010.07.008
  9. 201. Awada, A., Saliba, W., & Bozovic, I. (2011). Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. Drugs of today, 47(5), 335-345. doi:10.1358/dot.2011.47.5.1584110
  10. 202. Lalami, Y., & Awada, A. (2011). Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. Current opinion in oncology, 23(3), 235-240. doi:10.1097/CCO.0b013e3283448206
  11. 203. Villanueva, C., Awada, A., Campone, M., Machiels, J. P., Besse-Hammer, T., Magherini, E., Dubin, F., Semiond, D., & Pivot, X. (2011). A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. European journal of cancer, 47(7), 1037-1045. doi:10.1016/j.ejca.2011.01.001
  12. 204. Klastersky, J., & Awada, A. (2011). Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Critical reviews in oncology/hematology, 78(1), 17-23. doi:10.1016/j.critrevonc.2010.02.005
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>